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We recently reported that the heart expresses functional receptors for the anorexigenic 
glucagon-like peptide (GLP)-2. Activation of these cardiac receptors affected basal heart 
performance through extracellular regulated kinase (ERK1/2) activation. Since ERK1/2 is 
considered one of the prosurvival kinases of postconditioning cardioprotective pathways, we 
hypothesized that GLP-2 directly protects the heart against ischemia/reperfusion (I/R) injury 
via prosurvival kinases. Wistar rat hearts were retrogradely perfused on a Langendorff 
perfusion apparatus. After 40-min stabilization, hearts underwent 30-min global ischemia and 
120-min reperfusion (I/R group). In GLP-2 group, hearts received 20-min GLP-2 (10-7 M) 
infusion at the beginning of the 120-min reperfusion. Perfusion pressure and left ventricular 
pressure (LVP) were monitored. Infarct size was evaluated by nitroblue-tetrazolium staining. 
Compared with the I/R group, GLP-2 treated hearts showed a significant reduction of infarct 
size and of postischemic diastolic LVP (index of contracture), together with a sharp 
improvement of developed LVP recovery (index of contractility). The protective effects were 
abolished by co-infusion with phosphatidylinositol 3-Kinase inhibitor, Wortmannin, the 
ERK1/2 inhibitor, PD98059, or the mitochondrial KATP channel blocker, 5-
Hydroxydecanoate. GLP-2 effects were accompanied by increased phosphorylations of 
protein kinase B (PKB/Akt), ERK1/2 and glycogen synthase kinase (GSK3β). After 7-min 
reperfusion, Wortmannin blocked Akt and GSK3β phosphorylation. After 30-min 
reperfusion, Wortmannin inhibited phosphorylation of all kinases. In conclusion, data suggest 
that GLP-2, given in early reperfusion, as postconditioning, protects against myocardial I/R 
injury, limiting infarct size and improving post-ischemic mechanical recovery. It seems that 
the GLP-2-protection of rat heart involves multiple prosurvival kinases and mitochondrial 
KATP channels. 





Ischemic postconditioning applied immediately after a prolonged ischemic period attenuates 
infarct size. It can reduce infarct size, but, unfortunately, it cannot be applied to most patients, 
so a pharmacological postconditioning mimetic that can be administered at the onset of 
reperfusion to protect all acute myocardial infarction patients is necessary [14-18,31,43]. 
Several humoral factors control the cardiovascular system and the gastrointestinal apparatus, 
acting both directly on heart and vessels, and indirectly by controlling appetite, fluid intake 
and plasma osmolarity. Among these factors, two different peptides, glucagon-like peptide 1 
(GLP-1) and GLP-2, which are produced by intestinal L cells and co-released in response to 
food intake [10], have attracted the attention of researchers.  
GLP-1 has been extensively studied [e.g. 4,10,28,50]. On the contrary, GLP-2 is now 
emerging as a peptide with anorexigenic properties that plays a major role in short-term 
regulation of appetite and satiety, also profoundly influencing many gastrointestinal functions 
in healthy and in diabetes [11,25]. As such GLP-1 and GLP-2 represent a new class of drug 
which is emerging in ischemia scenario. Although extensive research supports a 
cardioprotective role for GLP-1 even in diabetes [4,28,50], nobody, to our knowledge, has 
studied whether GLP-2 protects the myocardium against ischemia/reperfusion (I/R) injury. 
This is not trivial because GLP-1 and GLP-2, by acting on different receptors may have 
different intracellular effects, especially on calcium handling [11,25]. Moreover, it has been 
suggested that GLP-1(9-36) cardioprotective effects do not require the classical GLP-1 
receptor [2]. Finally, GLP-2, like GLP-1, is of paramount importance in diabetes [11,25,50]. 
GLP-2 acts via a specific G protein-coupled receptor (GLP-2R), which is largely expressed in 
gastrointestinal tract [27] and brain [21,24,45]. It is also present in lung, cervix and vagal 
afferents [11]. Very recently, also the rat heart was found to express GLP-2R, whose 
activation depressed both basal and β-adrenergic stimulated inotropic (contractility) and 
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lusitropic (relaxation) performance [1]. These cardiac effects were independent from GLP-1 
receptor, involved Gi/o proteins and were associated with an increase in ERK1/2 activation in 
normal hearts [1]. 
Interestingly, ERK1/2 is one of the cardioprotective elements of “reperfusion injury salvage 
kinase (RISK) pathway” [9,15,17,37]. Actually, the RISK acronym was first used in a study 
in which the pharmacological inhibitor of ERK1/2, PD98059, abolished the infarct limiting 
effects of urocortin administered at reperfusion as postconditioning agent [37]. The RISK 
pathway, which seems necessary in rodents [14,18,20,38], is activated by both ischemic and 
pharmacological postconditioning [14,15,17,18,20,38,40,48,49]. This pathway includes 
glycogen synthase kinase (GSK3β), as a downstream target of both ERK1/2 and 
phosphatidylinositol 3-Kinase (PI3K)/protein kinase B (PKB/Akt). As such, GSK3β may act 
as a point of convergence for a variety of prosurvival signaling pathways resulting in 
mitochondrial mediated cardioprotection [12,14-18]. 
On the basis of the above described cardiovascular effects of GLP-2, the possibility exists 
that this peptide might exert cardioprotective effects under I/R conditions. Therefore, we 
tested whether GLP-2, applied immediately after an infarcting ischemia (i.e. as 
pharmacological postconditioning), may limit infarct size and may improve the recovery of 
post-ischemic cardiac function. Using pharmacological antagonists we also tested the 
hypothesis that activation of RISK pathway plays a role in GLP-2-induced cardioprotection, 
conveying the cardioprotective signal to mitochondria. Hence, using a mitochondrial KATP 
(mitoKATP) channel antagonist we tested the involvement of these protective channels [14-
16,20,31,38]. To corroborate pharmacological data, a direct involvement of Akt, ERK1/2 and 
GSK-β phosphorylation in GLP-2 reperfused heart was assessed by standard immunoblotting 




Materials and Methods 
Animals 
Male Wistar rats (Harlan Laboratories Srl, Udine, Italy), weighing 450-550 g, were housed 
(three per cage) in a ventilated cage rack system under standard conditions. Animals had food 
and water access ad libitum. The investigation conforms to Italian law (DL-116, January 27, 
1992) and to the Guide for the Care and Use of Laboratory Animals, according to National 
Institutes of Health publication 85-23 (revised 1996). The project was approved by the Italian 
Ministry of Health, Rome, and by the ethics review board of the University of Calabria. 
Isolated heart perfusion 
Rats were heparinized (2.500 units i.m.) and anesthetised with urethane (1 g/kg i.p.) 10-min 
later. The hearts were then rapidly excised, placed in ice-cold buffer solution, and weighed. 
Isolated hearts were attached to the perfusion apparatus and retrogradely perfused with 
oxygenated Krebs-Henseleit buffer (KHs) containing (in mM) 127 NaCl, 17.7 NaHCO3, 5.1 
KCl, 1.5 CaCl2, 1.26 MgCl2, and 11 D-glucose, supplemented with 5 µg/ml lidocaine and 
gassed with 95% O2-5% CO2 [6,29,30,32-34]. The perfusion pressure was set to 100 mmHg 
and kept constant throughout the experiments. The hearts were electrically paced at 280–300 
beats/min and kept in a temperature-controlled chamber (37°C). 
Drugs 
GLP-2 (rat) peptide was purchased from Tocris Bioscience. PD98059 (PD), a specific 
inhibitor of ERK1/2, Wortmannin (WT), a potent phosphatidylinositol 3-Kinase (PI3K) 
inhibitor, 5-Hydroxydecanoate (5HD), a mitoKATP channels blocker, were purchased from 





Each heart was allowed to stabilize for 40-min; at this time, baseline parameters were 
recorded. After stabilization, hearts were randomly assigned to one of the treatment groups 
described below and then subjected to 30-min of global, no-flow ischemia followed by 120-
min of reperfusion (I/R). Pacing was discontinued at the beginning of the ischemic period and 
restarted after the third minute of reperfusion [29,48]. 
Cardiac function and Infarct size studies (Fig 1, panel A) 
1) In the first group (I/R group; n=9), hearts were stabilized and subjected to I/R 
protocol only.  
2) In the second group (GLP-2 group, n=9), GLP-2 (10-7 M) was infused for 20-min at 
the beginning of 120-min reperfusion. 
3) In groups 3-5, hearts (n=9 for each group) were perfused with GLP-2 plus one of the 
following inhibitors: Wortmannin (WT, 10-7 M; GLP-2+WT), PD (10-8 M; GLP-
2+PD), or 5HD (10-5 M; GLP-2+5HD); perfusion with inhibitors started 5-min before 
ischemia and continued during the early 20-min of reperfusion in the presence of 
GLP-2 (10-7 M). 
4) In groups 6-8 hearts (n=8, for each group) were perfused with inhibitors only [WT 
(10-7M), PD (10-8M), or 5HD (10-5M)], which started 5-min before ischemia and 
continued during the early 20-min of reperfusion. 
The concentration of GLP-2 was chosen on the basis of a preliminary dose-response curve 
(10-12-10-7M) as the dose that induced the highest infarct size reduction (data not shown). In 
all experiments, the antagonist concentration was selected on the basis of previous reports 
[16,30,32,34], which have shown the efficacy of the selected concentrations. Hemodynamic 
parameters were assessed using a PowerLab data acquisition system and analyzed using 
Chart software (both purchased by ADInstruments, Basile, Italy).  
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Left ventricular end diastolic pressure (LVEDP) was used as an index of the extent of 
contracture development in reperfusion. In fact, contracture can be defined as an increase in 
LVEDP of 4 mmHg above the baseline level [29,30,32,34]. As index of contractile activity 
we used the developed left ventricular pressure (dLVP), which was calculated as the 
difference between systolic LVP and LVEDP. 
Assessment of myocardial injury 
To obtain infarct areas, hearts were rapidly removed from the perfusion apparatus at the end 
of reperfusion, and the left ventricle was dissected into 2- to 3-mm circumferential slices. 
After 20-min of incubation at 37°C in 0.1% solution of nitro blue tetrazolium in phosphate 
buffer, unstained necrotic tissue was carefully separated from stained viable tissue by an 
independent observer who was not aware of the nature of the intervention. The weights of the 
necrotic and non necrotic tissues were then determined, and the necrotic mass was expressed 
as a percentage of total left ventricular mass, including septum [29,30,32,34].  Since in 
isolated rat hearts, both pre- and post-conditioning are known to reduce the production of 
lactate dehydrogenase (LDH) during reperfusion, the release of this enzyme was tested in I/R 
and GLP-2 groups (n= 3 for both groups), as previously described [29,34]. 
Western blotting (Fig 1, panel B) 
To directly study whether GLP-2 is able to induce phosphorylation of upstream ERK1/2 and 
Akt, and downstream GSK3β, after 40-min stabilization, rat hearts underwent 30-min global 
ischemia followed by 7-min or 30-min reperfusion (n = 4 for each group). Therefore, two 
groups of hearts underwent I/R only (7 or 30-min reperfusion), two groups received GLP-2 in 
the early reperfusion (for 7 or 20-min), two groups received GLP-2 plus WT as described 
above (for 7 or 20-min in reperfusion), and two groups were perfused with physiological 
solution only (Sham) for 77 or 100-min, respectively. 
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The supernatants, corresponding to 60 µg protein, measured with Bradford’method [5], were 
subjected to SDS-PAGE on acrylamide gels (10% for Akt, phospho-Akt; GSK3β, phospho-
GSK3β, ERK1/2, phospho-ERK1/2) and transferred to PVDF membranes (GE Healthcare). 
Membranes were then incubated overnight at 4°C with the following primary antibodies: 
anti-Akt, anti-phospho-(Ser473)-Akt, anti-GSK3β, antiphospho-(Ser-9)-GSK3β, anti-
ERK1/2, anti-phospho-(Thr202/Tyr204)-ERK1/2 (Cell Signaling). To confirm equal protein 
loading, membranes were incubated with an anti-vinculin antibody (Sigma). Immunoblotted 
proteins were visualized using an Immuno-Star HRP Substrate Kit (Bio-Rad) and quantified 
by Kodak Image Station 440CF. Image analyses were performed by Kodak 1D 3.5 software 
[30,33]. The expression of total kinases and phospho-kinases for each heart was normalized 
with respect to its matched loading control vinculin, and data have been presented as the ratio 
of phospho to total kinases. 
Statistical analysis 
Data are expressed as the mean ± SEM. The statistical significance of differences within 
group was assessed using the ANOVA test. Comparison between groups was made by using 
a one-way analysis of variance (ANOVA) followed by the Bonferroni correction for post-hoc 
t-tests. Differences were considered to be statistically significant for p<0.05. 
 
Results 
In the baseline conditions hearts of all groups displayed similar cardiac function (data not 
shown). 
Improvement of postischemic cardiac function by GLP-2 involves survival kinases of the 
RISK pathway and mitoKATP channels (Fig 2). 
Systolic function in the post-ischemic phase is represented by the percent of developed dLVP 
recovery (i.e., inotropic activity). As can be seen in Fig 2A, the hearts of the I/R group 
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presented a limited dLVP recovery; in fact, at the end of reperfusion, the percent recovery of 
dLVP was 41±9% of baseline value (p<0.01 vs baseline). GLP-2 markedly improved the 
dLVP recovery during reperfusion, being it at the end of reperfusion 104±15% of the baseline 
(p<0.05 vs I/R group; Fig 2A). The GLP-2-dependent improvement of postischemic dLVP 
was abolished when the hearts were co-treated with GLP-2 plus the inhibitor of PI3K or 
ERK1/2 (WT or PD), or with the blocker (5HD) of mitoKATP channels. In hearts perfused 
with inhibitors only (groups 6-8), the recovery of systolic function was not different from I/R 
group (Fig 2B). 
Diastolic function (Fig 3) is represented by the level of contracture (i.e., LVEDP 4 mmHg or 
more above baseline level) [2,34]. I/R markedly increased LVEDP (from 6±1 mmHg in the 
baseline to 37±10 mmHg at the end of reperfusion, p<0.05). During reperfusion, GLP-2 
abolished contracture development; in fact, at the end of reperfusion, LVEDP was 6±1 
mmHg in GLP-2 group (p<0.001 vs I/R). The GLP-2-dependent improvement of 
postischemic contracture was abolished by co-treatment with GLP-2 plus the inhibitor of 
either PI3K or ERK1/2 (WT or PD), or with the mitoKATP channel blocker (5HD) (Fig 3A). 
In hearts perfused with inhibitors only (groups 6-8), the development of contracture was not 
different from I/R group (Fig 3B). 
GLP-2 induced reduction of infarct size is also linked to survival kinases and mitoKATP 
channels (Fig 4). 
Left ventricular (LV) mass was similar in all groups (LV weight was 927±13; range 559–
1105 mg). Total infarct size, expressed as a percentage of LV mass, was 65±8% in I/R. The 
infusion of GLP-2 during the early 20-min reperfusion reduced infarct size to 31±5% of LV 
mass (p<0.001 vs I/R). WT, PD or 5HD given in co-infusion with GLP-2 did not allow 
infarct size reduction; so that infarct size (61±3%, 59±4% and 60±3%, respectively) was not 
significantly different from that observed in I/R group (Fig 4A). In contrast, it resulted 
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significantly increased with respect to the hearts treated with GLP-2 alone (p<0.001 for each 
antagonist). In hearts perfused with inhibitors only (groups 6-8), infarct size was not different 
from I/R group (Fig 4B). 
To corroborate infarct size data, LDH release was analyzed in 3 hearts for I/R group and in 3 
hearts for GLP-2 group.  In these hearts of I/R group the cumulative LDH during reperfusion 
was 1197±125 U/g wet wt. In GLP-2 group the release of LDH was 907±96 U/g wet wt; a 
value significantly (p < 0.05) lower than that of I/R group. 
GLP2 induces the phosphorylation of upstream and downstream survival kinases of the 
RISK pathway (Figs 5 and 6). 
The involvement of kinases located upstream (Akt and ERK1/2) and downstream (GSK3β) 
of the protective pathway in the GLP-2 mechanism was evaluated by Western blotting 
analysis in two different time points, 7th and 30th min after start of reperfusion. Representative 
bands and densitometric analysis of the scanned blots are presented in Figs 5 and 6. Data are 
normalized with respect to the mean value of single value loading of vinculin. The infusion of 
GLP-2 enhanced phosphorylation for all kinases analyzed (Figs 5 and 6). In particular, at the 
7th min of reperfusion (Fig 5), the infusion of GLP-2 induced a remarkable phosphorylation 
of Akt and GSK3β (p<0.001 for both vs I/R), which were abolished by WT. A less evident 
phosphorylation of ERK1/2 was induced by GLP-2, regardless of the presence of WT (p< 
0.05 for both vs I/R, p= NS vs each other ), i.e. early ERK1/2 activation is PI3K-independent. 
At the 30th min of reperfusion, while the GLP-2 induced phosphorylation of Akt and GSK3β 
was less evident than that at the 7th min, the phosphorylation of ERK1/2 was similar at the 
two time points (Fig 6). However, the co-infusion with WT abolished the phosphorylation of 





This study demonstrates that GLP-2, given in the early reperfusion, has a significant 
protective effect against myocardial I/R injury. In particular, GLP-2 reduces infarct size and 
markedly improves the post-ischemic contractile function. Antagonists of upstream elements 
(PI3K and ERK1/2) of the RISK pathway, as well as blockade of mitochondrial KATP 
channels abrogate GLP-2 protective effects. This widens the influence of GLP-2 on the 
mammalian heart to cardioprotection, which has not been shown before. 
We recently described the cardiac profile of GLP-2 by revealing, in the rat heart, the presence 
of a functional GLP-2R, whose activation reduces baseline and beta-stimulated contractility. 
The cardiac effects of GLP-2 were independent from GLP-1 receptor, being unaffected by 
exendin-3 (9-39) amide [1]. Here, we aimed at evaluating the potential benefit of GLP-2 on 
postischemic myocardial function assessed in ex vivo model. GLP-2 given as 
postconditioning agent in early reperfusion decreases infarct size and markedly improves 
postischemic left ventricular function. These results are particularly relevant as alteration of 
LV function after infarction, and the presence of myocardial viability have been shown to be 
major determinants of mortality and prognosis after myocardial ischemia. These results are 
also relevant since the archetypal ischemic postconditioning protects against the extension of 
infarct size, but it does not significantly and constantly improve postischemic cardiac 
function [31 and references therein]. 
In non-ischemic models of different tissues, GLP-2 effects were mediated by the activation of 
the prosurvival kinases ERK1/2 [1] or by PI3K/Akt-mTOR signalling pathway [39]. Several 
studies have demonstrated that activation of G protein–coupled receptors may lead also to 
PI3K/Akt activation and cardioprotective effects [8,31]. The protective mechanisms activated 
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in reperfusion include at least two parallel pathways, which start from both ERK1/2 and 
PI3K-Akt and converge during reperfusion on GSK3β phosphorylation/inactivation with the 
involvement of mitoKATP channel opening [8,12,15,20,31,32]. Therefore, to evaluate whether 
GLP-2 improves post-ischemic cardiac function and cell survival via the activation of these 
two pathways, we inhibited the upstream kinases of the two parallel pathways (PI3K and 
ERK1/2). We also checked for the phosphorylation of components of the RISK pathway 
(Akt, ERK1/2 and GSK3β) during the early (7th min) and later (30th min) reperfusion period. 
Our findings suggest that the GLP-2-induced early protection takes place only if the two 
pathways (one starting from PI3K and the other from ERK1/2), and one of the terminal 
elements, mitoKATP channels, are simultaneously activated during early reperfusion. In fact, 
GLP-2 protection was abrogated by blocking each of these elements. Accordingly, these 
kinase-dependent signal transduction pathways may converge on mitochondria in 
postconditioning protection [8,12,15,31]. 
Several authors have shown that PI3K/Akt is involved in postconditioning 
[9,14,15,20,38,48,49]. Intriguingly, Darling et al. [9] have shown the involvement of ERK1/2 
rather than PI3K/Akt in the reduction of infarct size achieved with ischemic postconditioning. 
Here we show the strong involvement of PI3K/Akt in GLP-2 protection. In fact, Akt 
phosphorylation, after an initial sharp augmentation, decreases with time during reperfusion. 
Yet, ERK1/2 is involved in a less extent, but initially in a PI3K-independent fashion 
(unchanged by WT), and then persists in a PI3K-dependent manner (blocked by WT). These 
findings suggest a certain degree of cross-talk [49] and, perhaps, an additive protection 
between ERK1/2 and PI3K/Akt pathways in the early reperfusion phase. Therefore, it is 
likely that an adequate postconditioning stimulus can activate both pathways, thus leading to 
an improvement of postischemic cardiac function and to cell survival, as it is the case for 
GLP-2 in the present study. Since the inhibition of ERK1/2 activation by PD blocks the 
  
14
protective effects of GLP-2, our results suggest that the initial ERK1/2 phosphorylation is not 
an epiphenomenon and that both pathways are important to mediate cardioprotection. 
Accordingly, a total abrogation of postconditioning-induced protection was observed either 
inhibiting (PI3K)-Akt or ERK1/2 activation [17,41,46]. 
Clinical considerations 
In a recent “Special Report” it was stated that “improvements in morbidity and mortality can 
be achieved only with the development of new adjunctive therapies coupled with 
reperfusion” [38]. Importantly, in both animals and humans, administration of GLP-1 exerted 
cardiovascular effects [4,26,28,36,50]. Although Nikolaidis et al. [28] were the first to obtain 
improvements of cardiac function with GLP-1 in humans, their study was not designed to 
reduce lethal reperfusion injury, which occurs immediately after ischemia [8,15]. In fact 
GLP-1 was administered several hours after reperfusion, i.e. far from the therapeutic window 
for reperfusion injury [8,15]. 
Although GLP-2 has not been tested before in cardiac I/R scenario, it was shown to exhibit 
promising beneficial effects in several experimental models of intestinal atrophy and injury 
[7,23,35], including experimental intestinal ischemia [13,51]. The GLP-2 synthetic analogue, 
teduglutide ([gly2]-hGLP-2), is currently being developed as a potential therapeutic agent for 
patients with intestinal diseases [22]. All these data on the beneficial effects of GLP-2, 
together with the striking cardioprotective effect of GLP-2 here reported for the first time, 
provide new insights into the possible therapeutic potential for GLP-2 agonists, which might 
represent a new class of drugs to be tested for reducing cardiac I/R injury.  Of course future 
studies might ascertain the cardioprotective role of GLP-2 in the presence of comorbidities. 
Moreover alternative pathway(s), such as SAFE (Survivor Activating Factor Enhancement), 




In conclusion, GLP-2 reduces myocardial reperfusion injury, decreasing infarct size and 
improving post-ischemic cardiac function. It seems that in this rodent model both survival 
kinases and mitoKATP channels play important role in these cardioprotective effects. 
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Fig. 1. Experimental design.  
A. Cardiac function and Infarct size studies: Time-lines and protocols for all the experimental 
groups. After stabilization (40 min), all the hearts underwent 30-min normothermic and global 
ischemia followed by 120-min reperfusion, here represented with a sequence of white/black/white 
horizontal bars. Glucagon-like peptide 2 (GLP-2) was infused during the initial 20-min of 
reperfusion (gray bar). Wortmannin (WT) is a PI3K inhibitor, PD98059 (PD) is an ERK1/2 
inhibitor; 5-Hydroxydecanoate (5HD) is a mitoKATP channels blocker. Antagonists (PD, WT or 
5HD) were infused for 5-min prior ischemia and for 20-min after ischemia as indicated by 
horizontal black lines. 
B. Western blotting studies: Left ventricular samples of Sham groups (77 or 100-min buffer 
perfusion only), I/R groups, GLP-2 groups and a GLP-2 plus WT groups were considered for 
Western blot analysis. For further explanation see text. 
 
Fig. 2. Systolic function. 
Percent variation of developed LVP (dLVP): data are presented as percent changes at the end 
of 120-min reperfusion with respect to baseline level for each group. In Panel A are reported I/R, 
GLP-2 and GLP-2 plus inhibitors groups. In panel B are reported inhibitor-treated controls and 
for comparative purposes again I/R and GLP-2 groups. *p<0.01 with respect to I/R and each 
antagonist group. 
 
Fig. 3. Diastolic function. 
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Left ventricular end-diastolic pressure (LVEDP): data are expressed in mmHg at the end of 
120-min reperfusion. In Panel A are reported I/R, GLP-2 and GLP-2 plus inhibitors groups. In 
panel B are reported inhibitor-treated controls and for comparative purposes again I/R and GLP-2 
groups. **p<0.001 with respect to I/R and each antagonist group. 
 
Fig. 4. Infarct size.  
The amount of necrotic tissue measured after 30-min global ischemia and 120-min reperfusion is 
expressed as percent of the left ventricle (% IS/LV). In Panel A are reported I/R, GLP-2 and GLP-
2 plus inhibitors groups. In panel B are reported inhibitor-treated controls and for comparative 
purposes again I/R and GLP-2 groups. **p<0.001 with respect to I/R and each antagonist group. 
 
Fig. 5. Western blot analysis for RISK pathway at the 7th min of reperfusion.  
Representative Western blots and relative densitometry showing that GLP-2 given in early 
reperfusion results in an increase phosphorylation of Akt (Panel A), GSK3β (Panel B) and 
ERK1/2 (Panel C), with respect to I/R group. Wortmannin (WT) limits the phosphorylation of 
Akt, GSK3β, but not that of ERK1/2 (p = not significant between GLP-2 and GLP-2+WT). Total 
kinases and phospho-kinases for each heart are normalized to vinculin, and data are presented as 
the ratio of phospho to total kinases. Values are mean±SEM. * p< 0.05, ** p<0.01 with respect to 
I/R; # p< 0.05 with respect to Sham; § p< 0.05 with respect to GLP-2+WT. 
 
Fig. 6. Western blot analysis for RISK pathway at the 30th min of reperfusion. 
Representative Western blots and relative densitometry showing that GLP-2 given in early 
reperfusion results in the phosphorylation of Akt, GSK3β, and ERK1/2. GLP-2 induces an 
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increase in phospho-kinases. These phosphorylations are limited by Wortmannin (WT). Total 
kinases and phospho-kinases for each heart are normalized to vinculin, and data are presented as 
the ratio of phospho to total kinases. Values are mean±SEM. * p< 0.05 with respect to I/R; # p< 
0.05 with respect to Sham; § p< 0.05 with respect to GLP-2+WT. Please note that in Panel C the 
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